Emerging Perioperative Treatment Using Immune Checkpoint Inhibitors in Patients with Resectable NSCLC-IASLC Webinar_ Perioperative Treatment w_Immune Checkpoint Inhibitors in Patients w

IASLC Webinar_ Perioperative Treatment w_Immune Checkpoint Inhibitors in Patients w_Resectable NSCLC

Video Transcription

Video Summary

In this webinar, Dr. Enrique Ferp discussed the emerging preoperative treatment using immune checkpoint inhibitors in patients with resectable non-small cell lung cancer. He reviewed two trials, Empower 010 and Keynote 091, both of which demonstrated a disease-free survival benefit with adjuvant immunotherapy compared to standard care. In Empower 010, patients with stage 2 and 3A disease and PD-L1 positive tumors had longer disease-free survival with atezolizumab versus best supportive care. In Keynote 091, patients showed improved disease-free survival in the overall population and in those with PD-L1 50% or higher. Dr. Ferp also discussed the Checkmate 816 trial, which analyzed neoadjuvant chemotherapy plus nivolumab prior to surgery. This trial showed higher pathological complete response rates with the combination therapy. Dr. Ferp highlighted the need for more markers beyond PD-L1 and the potential value of circulating tumor DNA in individualizing therapy. He concluded that immunotherapy will become a standard of care for early stage non-small cell lung cancer, and the optimal use of adjuvant and neoadjuvant strategies will depend on patient characteristics and further research.

Keywords

webinar

preoperative treatment

immune checkpoint inhibitors

non-small cell lung cancer

disease-free survival

adjuvant immunotherapy

PD-L1 positive tumors

neoadjuvant chemotherapy

pathological complete response

circulating tumor DNA